Human Acellular Vessel
– A Controlled Comparison
of Efficacy and Safety Study
Patients with kidney failure who are currently receiving hemodialysis with a catheter (e.g. Permcath™) and require placement of a dialysis graft or creation of a dialysis fistula for more permanent dialysis access.
Approximately 20 Sites in the United States
Approximately 240 patients; Randomization: 1:1 AVF:HAV
STIUDY START DATE:
FOLLOW UP PERIOD:
Up to 5 years
Local Study coordinator
Thank you for being a part of the HAV-ACCESS clinical trial. This Phase III study will compare hemodialysis access with the Human Acellular Vessel (HAV) to that with an arteriovenous fistula (AVF), current standard of care for patients needing hemodialysis access. Thank you for your willingness to participate in important clinical research. Below you'll find more information about the HAV-ACCESS clinical trial, the Humacyte vessel and our technology.
Humacyte’s Study: A Controlled Comparison of Efficacy and Safety Study (HAV-ACCESS) between Humacyte’s Human Acellular Vessel (HAV) and a current clinical standard, arteriovenous fistula (AVF), for hemodialysis access began enrollment in August of 2017.
Patients with end-stage renal disease (kidney failure) who are currently receiving hemodialysis with a catheter (e.g. Permcath™) and who are suitable candidates for placement of a dialysis graft or creation of a dialysis fistula will be considered for participation in this prospective, multicenter, randomized, comparative study. Patients will be implanted in the forearm or upper arm with either a HAV or AVF. The 1:1 randomization (a 50/50 chance of receiving the HAV or AVF) will occur in the operating room, prior to surgery. All patients will be required to take daily aspirin unless they are already taking another antiplatelet agent e.g., Plavix® (clopidogrel)
Each patient will be followed by study specific visits through 2 years (24 months) of follow up after implantation (whether the study access is open and functioning or not). After 2 years, all subjects with HAV, but only those subjects with a functioning AVF will be followed for up to 5 years (60 months) post-implantation at routine study visits.
The HUMACYTE HAV is a tissue-engineered blood vessel that is being investigated as a surgical option for vascular access. The HAV is a sterile, vascular tube, composed of human connective tissue and proteins. This complex connective tissue has similarities to human vascular tissue but HAV is non-living. To date, the HAV has been implanted in over 250 patients worldwide in various clinical trials.
To read more about the Humacyte HAV, click here.